cilostazol has been researched along with Hemorrhage in 43 studies
Hemorrhage: Bleeding or escape of blood from a vessel.
| Excerpt | Relevance | Reference |
|---|---|---|
| "DAPT with cilostazol might be beneficial for prevention of recurrent stroke and vascular events in patients without arterial stenosis but not in those with ECAS." | 9.69 | Dual antiplatelet therapy with cilostazol in stroke patients with extracranial arterial stenosis or without arterial stenosis: A subgroup analysis of the CSPS.com trial. ( Hoshino, H; Kimura, K; Kitagawa, K; Minematsu, K; Okamura, S; Omae, K; Toyoda, K; Uchiyama, S; Yamaguchi, T, 2023) |
| "In patients with lacunar stroke, DAPT using cilostazol had significant benefits in reducing recurrent ischemic stroke incidence compared with SAPT without increasing the risk of severe or life-threatening bleeding." | 9.69 | Dual Antiplatelet Therapy With Cilostazol for Secondary Prevention in Lacunar Stroke: Subanalysis of the CSPS.com Trial. ( Hoshino, H; Houkin, K; Kimura, K; Matsumoto, M; Minematsu, K; Naritomi, H; Nishiyama, Y; Okada, Y; Origasa, H; Otsuka, T; Sakai, N; Terayama, Y; Tomimoto, H; Tominaga, T; Toyoda, K; Uchiyama, S; Yamaguchi, K; Yamaguchi, T; Yasuda, S, 2023) |
| "Cilostazol is feasible in acute ischemic stroke, and comparable to aspirin in its efficacy and safety." | 9.15 | Cilostazol in Acute Ischemic Stroke Treatment (CAIST Trial): a randomized double-blind non-inferiority trial. ( Bae, HJ; Cho, YJ; Han, MG; Hong, KS; Jung, SW; Kang, DW; Kim, DE; Kim, JS; Koo, J; Kwon, SU; Lee, BC; Lee, JH; Lee, KB; Lee, SH; Lee, SJ; Lee, YS; Park, JM; Rha, JH; Yu, K, 2011) |
| " We investigated the effects of cilostazol 200 mg, in addition to aspirin 100 mg and clopidogrel 75 mg, on carotid intima-media thickness (IMT) progression during a 2-year follow-up period in patients with acute coronary syndrome (ACS) requiring stent implantation." | 9.15 | Cilostazol reduces the progression of carotid intima-media thickness without increasing the risk of bleeding in patients with acute coronary syndrome during a 2-year follow-up. ( Ahn, CM; Hong, SJ; Kim, JS; Lim, DS; Park, JH, 2011) |
| "Although potent P2Y12 inhibitor-based dual antiplatelet therapy (DAPT) has replaced clopidogrel-based therapy as the standard treatment in patients with acute myocardial infarction (AMI), there is a concern about the risk of bleeding in East Asian patients." | 7.96 | Cilostazol-based triple versus potent P2Y12 inhibitor-based dual antiplatelet therapy in patients with acute myocardial infarction undergoing percutaneous coronary intervention. ( Byun, JK; Cha, J; Choi, BG; Choi, CU; Choi, JY; Choi, SY; Jang, WY; Jeong, MH; Kang, DO; Kim, EJ; Kim, JS; Kim, W; Na, JO; Oh, DJ; Park, CG; Park, Y; Rha, SW; Roh, SY; Seo, HS, 2020) |
| "The present study compared the effects of frequently used anti-platelet drugs, such as clopidogrel, ticlopidine, and cilostazol, on the gastric bleeding and ulcerogenic responses induced by intraluminal perfusion with 25 mM aspirin acidified with 25 mM HCl (acidified ASA) in rats." | 7.80 | Comparative effects of the anti-platelet drugs, clopidogrel, ticlopidine, and cilostazol on aspirin-induced gastric bleeding and damage in rats. ( Izuhara, C; Takayama, S; Takeuchi, K, 2014) |
| "It seems that these results showed the safety and efficacy of the enteric-coated aspirin in acute stroke care in Japanese patients." | 7.80 | Enteric-coated aspirin versus other antiplatelet drugs in acute non-cardioembolic ischemic stroke: post-marketing study in Japan. ( Inuyama, L; Mizuno, O; Sakaguchi, T; Takahashi, S; Yamada, T, 2014) |
| "In the non-rtPA cohort, pretreatment by cilostazol significantly decreased the endothelial expression of adhesion molecules (P-selectin and intercellular adhesion molecule-1) and prevented platelet aggregation and leukocyte plugging in the microvessels after cerebral ischemia/reperfusion in the acute phase." | 7.78 | Cilostazol, a phosphodiesterase inhibitor, prevents no-reflow and hemorrhage in mice with focal cerebral ischemia. ( Fujita, Y; Hase, Y; Ihara, M; Ito, H; Kitamura, A; Maki, T; Nakabayashi, H; Okamoto, Y; Takahashi, R; Washida, K, 2012) |
| "These platelets enhance thrombus formation at the sites of endothelial disruption." | 6.43 | Cilostazol: potential mechanism of action for antithrombotic effects accompanied by a low rate of bleeding. ( Goto, S, 2005) |
| "DAPT with cilostazol might be beneficial for prevention of recurrent stroke and vascular events in patients without arterial stenosis but not in those with ECAS." | 5.69 | Dual antiplatelet therapy with cilostazol in stroke patients with extracranial arterial stenosis or without arterial stenosis: A subgroup analysis of the CSPS.com trial. ( Hoshino, H; Kimura, K; Kitagawa, K; Minematsu, K; Okamura, S; Omae, K; Toyoda, K; Uchiyama, S; Yamaguchi, T, 2023) |
| "In patients with lacunar stroke, DAPT using cilostazol had significant benefits in reducing recurrent ischemic stroke incidence compared with SAPT without increasing the risk of severe or life-threatening bleeding." | 5.69 | Dual Antiplatelet Therapy With Cilostazol for Secondary Prevention in Lacunar Stroke: Subanalysis of the CSPS.com Trial. ( Hoshino, H; Houkin, K; Kimura, K; Matsumoto, M; Minematsu, K; Naritomi, H; Nishiyama, Y; Okada, Y; Origasa, H; Otsuka, T; Sakai, N; Terayama, Y; Tomimoto, H; Tominaga, T; Toyoda, K; Uchiyama, S; Yamaguchi, K; Yamaguchi, T; Yasuda, S, 2023) |
| " The addition of cilostazol to clopidogrel may provide a more rapid decrease in PRU to therapeutic levels without increasing the risk of hemorrhage." | 5.30 | DAPT Plus Cilostazol is Better Than Traditional DAPT or Aspirin Plus Ticagrelor as Elective PCI for Intermediate-to-Highly Complex Cases: Prospective, Randomized, PRU-Based Study in Taiwan. ( Chang, CC; Chen, SM; Chen, YC; Cheng, SM; Chuang, CL; Lin, FY; Lin, RH; Lin, YW; Sheu, JS; Tsai, CS, 2019) |
| "Cilostazol, a phosphodiesterase III inhibitor, has vasodilating and antiplatelet properties with a low rate of bleeding complications." | 5.22 | Update on Cilostazol: A Critical Review of Its Antithrombotic and Cardiovascular Actions and Its Clinical Applications. ( Manolis, AA; Manolis, AS; Manolis, TA; Melita, H; Mikhailidis, DP, 2022) |
| " Cilostazol proved to be the most efficacious in reducing stroke recurrence and the risk of bleeding (RR = 0." | 5.22 | Antithrombotic therapy for secondary prevention in patients with stroke or transient ischemic attack: A multiple treatment network meta-analysis of randomized controlled trials. ( Bálint, A; El Abdallaoui, OEA; Komócsi, A; Kupó, P; Szapáry, L; Szapáry, LB; Tornyos, D, 2022) |
| "Cilostazol is feasible in acute ischemic stroke, and comparable to aspirin in its efficacy and safety." | 5.15 | Cilostazol in Acute Ischemic Stroke Treatment (CAIST Trial): a randomized double-blind non-inferiority trial. ( Bae, HJ; Cho, YJ; Han, MG; Hong, KS; Jung, SW; Kang, DW; Kim, DE; Kim, JS; Koo, J; Kwon, SU; Lee, BC; Lee, JH; Lee, KB; Lee, SH; Lee, SJ; Lee, YS; Park, JM; Rha, JH; Yu, K, 2011) |
| " We investigated the effects of cilostazol 200 mg, in addition to aspirin 100 mg and clopidogrel 75 mg, on carotid intima-media thickness (IMT) progression during a 2-year follow-up period in patients with acute coronary syndrome (ACS) requiring stent implantation." | 5.15 | Cilostazol reduces the progression of carotid intima-media thickness without increasing the risk of bleeding in patients with acute coronary syndrome during a 2-year follow-up. ( Ahn, CM; Hong, SJ; Kim, JS; Lim, DS; Park, JH, 2011) |
| "Cilostazol, a phosphodiesterase III inhibitor, is indicated to treat the symptoms of intermittent claudication and increase walking distance in patients with peripheral arterial disease (PAD)." | 5.13 | Long-term safety of cilostazol in patients with peripheral artery disease: the CASTLE study (Cilostazol: A Study in Long-term Effects). ( Brass, EP; Hiatt, WR; Money, SR, 2008) |
| "Cilostazol was significantly more effective than aspirin and clopidogrel alone in the long-term prevention of serious vascular events in patients with prior non-cardioembolic ischaemic stroke or transient ischaemic attack." | 4.93 | Antiplatelet regimens in the long-term secondary prevention of transient ischaemic attack and ischaemic stroke: an updated network meta-analysis. ( Guo, ZN; Jin, H; Niu, PP; Xing, YQ; Yang, Y, 2016) |
| "Although potent P2Y12 inhibitor-based dual antiplatelet therapy (DAPT) has replaced clopidogrel-based therapy as the standard treatment in patients with acute myocardial infarction (AMI), there is a concern about the risk of bleeding in East Asian patients." | 3.96 | Cilostazol-based triple versus potent P2Y12 inhibitor-based dual antiplatelet therapy in patients with acute myocardial infarction undergoing percutaneous coronary intervention. ( Byun, JK; Cha, J; Choi, BG; Choi, CU; Choi, JY; Choi, SY; Jang, WY; Jeong, MH; Kang, DO; Kim, EJ; Kim, JS; Kim, W; Na, JO; Oh, DJ; Park, CG; Park, Y; Rha, SW; Roh, SY; Seo, HS, 2020) |
| "Cilostazol has been associated with spontaneous reports of cardiovascular adverse events and serious bleeding." | 3.88 | Safety of cilostazol in peripheral artery disease: a cohort from a primary healthcare electronic database. ( Alzamora, M; Forés, R; Giner-Soriano, M; Heras, A; Marsal, JR; Morros, R; Pera, G; Real, J; Ribes, E; Serna, MC, 2018) |
| "Cilostazol was associated with a significant reduction in late loss in BMS (mean difference 0." | 3.84 | Efficacy of cilostazol in reducing restenosis in patients undergoing contemporary stent based PCI: a meta-analysis of randomised controlled trials. ( Chen, KY; Chetcuti, S; Grossman, MP; Gurm, H; Meier, P; Rha, SW; Tamhane, U, 2009) |
| "Sarpogrelate-containing triple antiplatelet therapy demonstrated comparable rates of MACCE prevention to the conventional dual antiplatelet therapy after PCI without significantly increasing bleeding risk during the two-year follow-up period." | 3.83 | Antiplatelet Therapy of Cilostazol or Sarpogrelate with Aspirin and Clopidogrel after Percutaneous Coronary Intervention: A Retrospective Cohort Study Using the Korean National Health Insurance Claim Database. ( Bae, SK; Kim, GJ; Kim, JH; Lee, J; Lee, S; Lim, HS; Noh, Y; Oh, E; Shin, S, 2016) |
| "We used data from the FRENA Registry to compare the clinical outcome in stable outpatients with intermittent claudication, according to the use of cilostazol." | 3.80 | Cilostazol and outcome in outpatients with peripheral artery disease. ( Aguilar, E; Esteban, C; Jiménez Caballero, PE; Manzano, L; Monreal, M; Mujal, A; Perez, P; Sánchez Muñoz-Torrero, JF; Sauquillo, JC; Yeste, M, 2014) |
| "It seems that these results showed the safety and efficacy of the enteric-coated aspirin in acute stroke care in Japanese patients." | 3.80 | Enteric-coated aspirin versus other antiplatelet drugs in acute non-cardioembolic ischemic stroke: post-marketing study in Japan. ( Inuyama, L; Mizuno, O; Sakaguchi, T; Takahashi, S; Yamada, T, 2014) |
| "The present study compared the effects of frequently used anti-platelet drugs, such as clopidogrel, ticlopidine, and cilostazol, on the gastric bleeding and ulcerogenic responses induced by intraluminal perfusion with 25 mM aspirin acidified with 25 mM HCl (acidified ASA) in rats." | 3.80 | Comparative effects of the anti-platelet drugs, clopidogrel, ticlopidine, and cilostazol on aspirin-induced gastric bleeding and damage in rats. ( Izuhara, C; Takayama, S; Takeuchi, K, 2014) |
| "In the non-rtPA cohort, pretreatment by cilostazol significantly decreased the endothelial expression of adhesion molecules (P-selectin and intercellular adhesion molecule-1) and prevented platelet aggregation and leukocyte plugging in the microvessels after cerebral ischemia/reperfusion in the acute phase." | 3.78 | Cilostazol, a phosphodiesterase inhibitor, prevents no-reflow and hemorrhage in mice with focal cerebral ischemia. ( Fujita, Y; Hase, Y; Ihara, M; Ito, H; Kitamura, A; Maki, T; Nakabayashi, H; Okamoto, Y; Takahashi, R; Washida, K, 2012) |
| "Cilostazol is a unique antiplatelet agent that has been commercially available for over two decades." | 2.52 | Clinical efficacy and safety of cilostazol: a critical review of the literature. ( Finks, SW; Oliphant, CS; Rogers, KC, 2015) |
| "Four studies including 1005 patients reporting the adverse clinical outcomes and six studies including 519 patients reporting the platelet activities, with a total of 1524 patients have been analyzed in this meta-analysis." | 2.52 | Comparing the effectiveness and safety between triple antiplatelet therapy and dual antiplatelet therapy in type 2 diabetes mellitus patients after coronary stents implantation: a systematic review and meta-analysis of randomized controlled trials. ( Bundhun, PK; Chen, MH; Qin, T, 2015) |
| " The included end-points were major adverse cardiovascular event (MACE), target lesion revascularization (TLR), target vessel revascularization (TVR), death, myocardial infarction (MI), stent thrombosis, bleeding and other drug adverse events." | 2.50 | Long-term clinical efficacy and safety of adding cilostazol to dual antiplatelet therapy for patients undergoing PCI: a meta-analysis of randomized trials with adjusted indirect comparisons. ( Chen, Y; Huang, X; Tang, Y; Xie, Y; Zhang, Y, 2014) |
| "These platelets enhance thrombus formation at the sites of endothelial disruption." | 2.43 | Cilostazol: potential mechanism of action for antithrombotic effects accompanied by a low rate of bleeding. ( Goto, S, 2005) |
| "TAT under TEG guidance appears to be a safe antiplatelet strategy in patients undergoing stenting for extracranial and/or intracranial artery stenosis." | 1.51 | The safety of triple antiplatelet therapy under thromboelastography guidance in patients undergoing stenting for ischemic cerebrovascular disease. ( Jiang, WJ; Li, C; Liu, AF; Qiu, H; Wang, K; Wu, Z; Zhang, Y; Zhou, J, 2019) |
| "Cilostazol is an antiplatelet drug often used in Asian countries like Korea, Japan, and China." | 1.42 | Cilostazol research in Asia: can it be applied to European and American patients? ( Kim, JS; Kwon, SU; Uchiyama, S, 2015) |
| "6 months, major adverse cardiac and cerebrovascular events (MACCE) occurred in 43 patients (17." | 1.39 | Long-term effectiveness and safety of triple versus dual antiplatelet therapy after percutaneous coronary intervention for unprotected left main coronary artery disease. ( Choi, RK; Hwang, HK; Lee, HJ; Li, H; Park, JS; Ro, YM; Yu, CW, 2013) |
| "Mice subjected to 6-h middle cerebral artery occlusion were treated with delayed tPA alone at 6 h, with combined tPA plus cilostazol at 6 h, or with vehicle at 6 h." | 1.36 | Phosphodiesterase-III inhibitor prevents hemorrhagic transformation induced by focal cerebral ischemia in mice treated with tPA. ( Chen, H; Fujiwara, Y; Hara, H; Ishiguro, M; Iwama, T; Izuta, H; Mishiro, K; Satoh, M; Shimazawa, M; Tsuruma, K; Yoshimura, S, 2010) |
| " At 7 and 30 days, the composite outcome for the group treated with cilostazol alone and that treated with abciximab in combination with cilostazol did not differ significantly." | 1.34 | Efficacy and safety of abciximab in combination with cilostazol in patients undergoing stenting. ( Hong, EH; Kim, MY; Lee, MH; Oh, JM; Park, JE; Shin, WG, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (16.28) | 29.6817 |
| 2010's | 28 (65.12) | 24.3611 |
| 2020's | 8 (18.60) | 2.80 |
| Authors | Studies |
|---|---|
| Manolis, AA | 1 |
| Manolis, TA | 1 |
| Melita, H | 1 |
| Mikhailidis, DP | 1 |
| Manolis, AS | 1 |
| Uchiyama, S | 4 |
| Toyoda, K | 2 |
| Okamura, S | 1 |
| Omae, K | 1 |
| Hoshino, H | 2 |
| Kimura, K | 2 |
| Kitagawa, K | 1 |
| Minematsu, K | 2 |
| Yamaguchi, T | 2 |
| Tornyos, D | 1 |
| Komócsi, A | 1 |
| Bálint, A | 1 |
| Kupó, P | 1 |
| El Abdallaoui, OEA | 1 |
| Szapáry, L | 1 |
| Szapáry, LB | 1 |
| Liu, H | 1 |
| Shao, T | 1 |
| Yang, T | 1 |
| Li, D | 1 |
| Wang, H | 1 |
| Cheng, Y | 1 |
| Zhang, T | 1 |
| Zhang, J | 1 |
| Nishiyama, Y | 1 |
| Otsuka, T | 1 |
| Sakai, N | 1 |
| Okada, Y | 1 |
| Origasa, H | 1 |
| Naritomi, H | 1 |
| Houkin, K | 1 |
| Yamaguchi, K | 1 |
| Matsumoto, M | 1 |
| Tominaga, T | 1 |
| Tomimoto, H | 1 |
| Terayama, Y | 1 |
| Yasuda, S | 1 |
| Neishi, M | 1 |
| Hamano, H | 1 |
| Niimura, T | 1 |
| Denda, M | 1 |
| Yagi, K | 1 |
| Miyata, K | 1 |
| Lin, TJ | 1 |
| Higashionna, T | 1 |
| Goda, M | 1 |
| Zamami, Y | 1 |
| Ishizawa, K | 1 |
| Nawa, H | 1 |
| Kim, W | 1 |
| Kim, JS | 4 |
| Rha, SW | 2 |
| Choi, BG | 1 |
| Jang, WY | 1 |
| Kang, DO | 1 |
| Park, Y | 2 |
| Choi, JY | 1 |
| Roh, SY | 1 |
| Na, JO | 1 |
| Choi, CU | 1 |
| Kim, EJ | 1 |
| Park, CG | 1 |
| Seo, HS | 1 |
| Choi, SY | 1 |
| Byun, JK | 1 |
| Cha, J | 1 |
| Oh, DJ | 1 |
| Jeong, MH | 2 |
| Dai, C | 1 |
| Chen, Z | 1 |
| Fu, J | 1 |
| Qian, J | 1 |
| Ge, J | 1 |
| Jang, HJ | 1 |
| Park, SD | 1 |
| Park, HW | 1 |
| Suh, J | 1 |
| Oh, PC | 1 |
| Moon, J | 1 |
| Lee, K | 1 |
| Kang, WC | 1 |
| Kwon, SW | 1 |
| Kim, TH | 1 |
| Real, J | 1 |
| Serna, MC | 1 |
| Giner-Soriano, M | 1 |
| Forés, R | 1 |
| Pera, G | 1 |
| Ribes, E | 1 |
| Alzamora, M | 1 |
| Marsal, JR | 1 |
| Heras, A | 1 |
| Morros, R | 1 |
| Daimon, S | 1 |
| Wu, Z | 1 |
| Liu, AF | 1 |
| Zhou, J | 1 |
| Zhang, Y | 2 |
| Wang, K | 1 |
| Li, C | 1 |
| Qiu, H | 1 |
| Jiang, WJ | 1 |
| Zhao, S | 1 |
| Zhong, Z | 1 |
| Qi, G | 1 |
| Shi, L | 1 |
| Tian, W | 1 |
| Chen, YC | 1 |
| Lin, FY | 1 |
| Lin, YW | 1 |
| Cheng, SM | 1 |
| Lin, RH | 1 |
| Chuang, CL | 1 |
| Sheu, JS | 1 |
| Chen, SM | 1 |
| Chang, CC | 1 |
| Tsai, CS | 1 |
| Lee, HJ | 1 |
| Yu, CW | 1 |
| Hwang, HK | 1 |
| Choi, RK | 1 |
| Park, JS | 1 |
| Li, H | 1 |
| Ro, YM | 1 |
| Park, KW | 1 |
| Kang, SH | 1 |
| Park, JJ | 1 |
| Yang, HM | 1 |
| Kang, HJ | 1 |
| Koo, BK | 1 |
| Park, BE | 1 |
| Cha, KS | 1 |
| Rhew, JY | 1 |
| Jeon, HK | 1 |
| Shin, ES | 1 |
| Oh, JH | 1 |
| Kim, S | 1 |
| Hwang, KK | 1 |
| Yoon, JH | 1 |
| Lee, SY | 1 |
| Park, TH | 1 |
| Moon, KW | 1 |
| Kwon, HM | 1 |
| Chae, IH | 1 |
| Kim, HS | 1 |
| Chen, Y | 1 |
| Tang, Y | 1 |
| Huang, X | 1 |
| Xie, Y | 1 |
| Nakagawa, I | 2 |
| Wada, T | 2 |
| Park, HS | 2 |
| Nishimura, F | 1 |
| Yamada, S | 2 |
| Nakagawa, H | 1 |
| Kichikawa, K | 2 |
| Nakase, H | 2 |
| Takahashi, S | 1 |
| Mizuno, O | 1 |
| Sakaguchi, T | 1 |
| Yamada, T | 1 |
| Inuyama, L | 1 |
| Perez, P | 1 |
| Esteban, C | 1 |
| Sauquillo, JC | 1 |
| Yeste, M | 1 |
| Manzano, L | 1 |
| Mujal, A | 1 |
| Jiménez Caballero, PE | 1 |
| Aguilar, E | 1 |
| Sánchez Muñoz-Torrero, JF | 1 |
| Monreal, M | 1 |
| Takeuchi, K | 1 |
| Takayama, S | 1 |
| Izuhara, C | 1 |
| Kwon, SU | 2 |
| Rogers, KC | 1 |
| Oliphant, CS | 1 |
| Finks, SW | 1 |
| Bundhun, PK | 1 |
| Qin, T | 1 |
| Chen, MH | 1 |
| Noh, Y | 1 |
| Lee, J | 1 |
| Shin, S | 1 |
| Lim, HS | 1 |
| Bae, SK | 1 |
| Oh, E | 1 |
| Kim, GJ | 1 |
| Kim, JH | 1 |
| Lee, S | 1 |
| Niu, PP | 1 |
| Guo, ZN | 1 |
| Jin, H | 1 |
| Xing, YQ | 1 |
| Yang, Y | 1 |
| Otoshi, T | 1 |
| Kataoka, Y | 1 |
| Nakagawa, A | 1 |
| Otsuka, K | 1 |
| Tomii, K | 1 |
| Zuliani Mauro, MF | 1 |
| Mangione, JA | 1 |
| Costa, JR | 1 |
| Costa, R | 1 |
| Piva E Mattos, LA | 1 |
| Staico, R | 1 |
| Feres, F | 1 |
| Siqueira, D | 1 |
| Sousa, A | 1 |
| Abizaid, A | 1 |
| Yokoyama, S | 1 |
| Motoyama, Y | 1 |
| Tamhane, U | 1 |
| Meier, P | 1 |
| Chetcuti, S | 1 |
| Chen, KY | 1 |
| Grossman, MP | 1 |
| Gurm, H | 1 |
| Jeong, YH | 1 |
| Kim, IS | 1 |
| Yun, SE | 1 |
| Kang, MK | 1 |
| Hwang, SJ | 1 |
| Kwak, CH | 1 |
| Hwang, JY | 1 |
| Ishiguro, M | 1 |
| Mishiro, K | 1 |
| Fujiwara, Y | 1 |
| Chen, H | 1 |
| Izuta, H | 1 |
| Tsuruma, K | 1 |
| Shimazawa, M | 1 |
| Yoshimura, S | 1 |
| Satoh, M | 1 |
| Iwama, T | 1 |
| Hara, H | 1 |
| Ahn, CM | 1 |
| Hong, SJ | 1 |
| Park, JH | 1 |
| Lim, DS | 1 |
| Lee, YS | 1 |
| Bae, HJ | 1 |
| Kang, DW | 1 |
| Lee, SH | 1 |
| Yu, K | 1 |
| Park, JM | 1 |
| Cho, YJ | 1 |
| Hong, KS | 1 |
| Kim, DE | 1 |
| Lee, KB | 1 |
| Rha, JH | 1 |
| Koo, J | 1 |
| Han, MG | 1 |
| Lee, SJ | 1 |
| Lee, JH | 1 |
| Jung, SW | 1 |
| Lee, BC | 1 |
| Pant, S | 1 |
| Neupane, P | 1 |
| Ramesh, KC | 1 |
| Barakoti, M | 1 |
| Hase, Y | 1 |
| Okamoto, Y | 1 |
| Fujita, Y | 1 |
| Kitamura, A | 1 |
| Nakabayashi, H | 1 |
| Ito, H | 1 |
| Maki, T | 1 |
| Washida, K | 1 |
| Takahashi, R | 1 |
| Ihara, M | 1 |
| Geng, DF | 1 |
| Liu, M | 1 |
| Jin, DM | 1 |
| Wu, W | 1 |
| Deng, J | 1 |
| Wang, JF | 1 |
| Goto, S | 2 |
| Nakamura, T | 1 |
| Yamazaki, M | 1 |
| Kimura, Y | 1 |
| Iwata, M | 1 |
| Liao, JK | 1 |
| Hong, EH | 1 |
| Kim, MY | 1 |
| Park, JE | 1 |
| Lee, MH | 1 |
| Oh, JM | 1 |
| Shin, WG | 1 |
| Hiatt, WR | 1 |
| Money, SR | 1 |
| Brass, EP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT02101411] | 334 participants (Actual) | Observational | 2015-01-01 | Completed | |||
| Comparison of the Efficacy and Safety of New Platform Everolimus-eluting Coronary Stent System (Promus Element) With Zotarolimus-eluting Coronary Stent System (Endeavor Resolute) and Triple Anti-platelet Therapy With Double-dose Clopidogrel Anti-platelet [NCT01267734] | Phase 4 | 3,750 participants (Anticipated) | Interventional | 2010-06-30 | Recruiting | ||
| Study of the Efficacy and Safety of Cilostazol in the Prevention of Ischemic Vascular Events in Diabetic Patients With Symptomatic Peripheral Artery Disease.[NCT02983214] | Phase 4 | 826 participants (Actual) | Interventional | 2016-11-30 | Completed | ||
| The Double-Blind, Randomized, Multi-Center, and Active Controlled Trial for Efficacy and Safety of Cilostazol in Acute Ischemic Stroke[NCT00272454] | Phase 4 | 468 participants (Anticipated) | Interventional | 2006-01-31 | Completed | ||
| Evaluation of Cilostazol in Combination With L-Carnitine in Subjects With Intermittent Claudication[NCT00822172] | Phase 4 | 164 participants (Actual) | Interventional | 2008-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
MACE(major adverse cardiac event) include: death, myocardial infarction, revascularization. (NCT02101411)
Timeframe: 24 months
| Intervention | numbers of participants with MACE (Number) |
|---|---|
| Aspirin+Clopidogrel | 1 |
| Aspirin+Ticagrelor | 1 |
| Aspirin+Clopidogrel+Cilostazol | 2 |
Subjects were asked to complete a standardized exercise treadmill test using a modified Gardner protocol. Subjects walked on the treadmill until they were physically unable to walk further either as a result of their peripheral artery disease (PAD) symptoms or other non-PAD symptoms. The time during the conduct of the exercise treadmill test at which the subject first reported claudication symptoms is referred to as the claudication onset time (COT) and reported in minutes/seconds. The exercise treadmill test was conducted at Screening, Baseline, Day 90, and Day 180 visits. The log transformation is used to make highly skewed distributions less skewed. (NCT00822172)
Timeframe: Baseline, Day 180
| Intervention | Log Minutes (Mean) |
|---|---|
| Cilostazol + L-Carnitine | 1.065 |
| Cilostazol + Placebo | 0.896 |
Subjects were asked to complete a standardized exercise treadmill test using a modified Gardner protocol. Subjects walked on the treadmill until they were physically unable to walk further either as a result of their peripheral artery disease (PAD) symptoms or other non-PAD symptoms. The time during the conduct of the exercise treadmill test at which the subject first reported claudication symptoms is referred to as the claudication onset time (COT) and reported in minutes/seconds. The exercise treadmill test was conducted at Screening, Baseline, Day 90, and Day 180 visits. The log transformation is used to make highly skewed distributions less skewed. (NCT00822172)
Timeframe: Baseline, Day 90
| Intervention | Log Minutes (Mean) |
|---|---|
| Cilostazol + L-Carnitine | 1.001 |
| Cilostazol + Placebo | 0.815 |
Subjects were asked to complete a standardized exercise treadmill test using a modified Gardner protocol. Subjects walked on the treadmill until they were physically unable to walk further either as a result of their peripheral artery disease (PAD) symptoms or other non-PAD symptoms. This maximum time walked is referred to as the peak walking time (PWT) and reported in minutes/seconds. The exercise treadmill test was conducted at Screening, Baseline, Day 90, and Day 180 visits. The log transformation is used to make highly skewed distributions less skewed. (NCT00822172)
Timeframe: Baseline, Day 180
| Intervention | Log Minutes (Mean) |
|---|---|
| Cilostazol + L-Carnitine | 0.241 |
| Cilostazol + Placebo | 0.134 |
Subjects were asked to complete a standardized exercise treadmill test using a modified Gardner protocol. Subjects walked on the treadmill until they were physically unable to walk further either as a result of their peripheral artery disease (PAD) symptoms or other non-PAD symptoms. This maximum time walked is referred to as the peak walking time (PWT) and reported in minutes/seconds. The exercise treadmill test was conducted at Screening, Baseline, Day 90, and Day 180 visits. The log transformation is used to make highly skewed distributions less skewed. (NCT00822172)
Timeframe: Baseline, Day 180
| Intervention | Log Minutes (Mean) |
|---|---|
| Cilostazol + L-Carnitine | 0.267 |
| Cilostazol + Placebo | 0.145 |
Subjects were asked to complete a standardized exercise treadmill test using a modified Gardner protocol. Subjects walked on the treadmill until they were physically unable to walk further either as a result of their peripheral artery disease (PAD) symptoms or other non-PAD symptoms. This maximum time walked is referred to as the peak walking time (PWT) and reported in minutes/seconds. The exercise treadmill test was conducted at Screening, Baseline, Day 90, and Day 180 visits. The log transformation is used to make highly skewed distributions less skewed. (NCT00822172)
Timeframe: Baseline, Day 90
| Intervention | Log Minutes (Mean) |
|---|---|
| Cilostazol + L-Carnitine | 0.166 |
| Cilostazol + Placebo | 0.139 |
Subjects completed the Walking Impairment Questionnaire (WIQ) whereby they were asked about their maximal walking distance before having to rest as a result of claudication symptoms associated with their peripheral artery disease (PAD). The WIQ was administered at the Baseline, Day 90, and Day 180 visits. On the WIQ subjects were asked a series of questions related to their degree of physical difficulty that best described how hard it was for the subject to walk on level ground without stopping to rest. The questions began by asking the degree of difficulty walking around indoors, then 50 feet, 150 feet, 300 feet, 600 feet, 900 feet, and lastly 1500 feet. The responses range from None (best outcome) to Slight, then Some, then Much, then lastly Unable (worst outcome). The walking distance score was calculated from the 7 questions in the section by way of a weighted sum. A score of 100 indicated no walking impairment. A score of 0 corresponded to the highest degree of walking impairment (NCT00822172)
Timeframe: Baseline, Day 180
| Intervention | score on a scale (Mean) |
|---|---|
| Cilostazol + L-Carnitine | 13.20 |
| Cilostazol + Placebo | 6.57 |
Subjects completed the Walking Impairment Questionnaire (WIQ) whereby they were asked about their maximal walking distance before having to rest as a result of claudication symptoms associated with their peripheral artery disease (PAD). The WIQ was administered at the Baseline, Day 90, and Day 180 visits. On the WIQ subjects were asked a series of questions related to their degree of physical difficulty that best described how hard it was for the subject to walk on level ground without stopping to rest. The questions began by asking the degree of difficulty walking around indoors, then 50 feet, 150 feet, 300 feet, 600 feet, 900 feet, and lastly 1500 feet. The responses range from None (best outcome) to Slight, then Some, then Much, then lastly Unable (worst outcome). The walking distance score was calculated from the 7 questions in the section by way of a weighted sum. A score of 100 indicated no walking impairment. A score of 0 corresponded to the highest degree of walking impairment (NCT00822172)
Timeframe: Baseline, Day 90
| Intervention | score on a scale (Mean) |
|---|---|
| Cilostazol + L-Carnitine | 12.98 |
| Cilostazol + Placebo | 10.01 |
12 reviews available for cilostazol and Hemorrhage
| Article | Year |
|---|---|
Update on Cilostazol: A Critical Review of Its Antithrombotic and Cardiovascular Actions and Its Clinical Applications.
Topics: Animals; Cilostazol; Coronary Artery Disease; Diabetes Mellitus, Type 2; Drug Therapy, Combination; | 2022 |
Antithrombotic therapy for secondary prevention in patients with stroke or transient ischemic attack: A multiple treatment network meta-analysis of randomized controlled trials.
Topics: Aspirin; Cilostazol; Fibrinolytic Agents; Hemorrhage; Humans; Ischemic Attack, Transient; Ischemic S | 2022 |
Effects of Cilostazol-Based Triple Antiplatelet Therapy Versus Dual Antiplatelet Therapy After Coronary Drug-Eluting Stent Implantation: An Updated Meta-Analysis of the Randomized Controlled Trials.
Topics: Cilostazol; Drug Therapy, Combination; Drug-Eluting Stents; Hemorrhage; Humans; Myocardial Infarctio | 2019 |
Long-term clinical efficacy and safety of adding cilostazol to dual antiplatelet therapy for patients undergoing PCI: a meta-analysis of randomized trials with adjusted indirect comparisons.
Topics: Aspirin; Cilostazol; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combination; Hemorrhage; Humans | 2014 |
Clinical efficacy and safety of cilostazol: a critical review of the literature.
Topics: Animals; Cilostazol; Hemorrhage; Humans; Intermittent Claudication; Peripheral Arterial Disease; Pla | 2015 |
Comparing the effectiveness and safety between triple antiplatelet therapy and dual antiplatelet therapy in type 2 diabetes mellitus patients after coronary stents implantation: a systematic review and meta-analysis of randomized controlled trials.
Topics: Acute Coronary Syndrome; Aspirin; Cilostazol; Clopidogrel; Coronary Artery Disease; Diabetes Mellitu | 2015 |
Antiplatelet regimens in the long-term secondary prevention of transient ischaemic attack and ischaemic stroke: an updated network meta-analysis.
Topics: Aspirin; Cilostazol; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Hemorrhage; Humans; Ische | 2016 |
Efficacy of cilostazol in reducing restenosis in patients undergoing contemporary stent based PCI: a meta-analysis of randomised controlled trials.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Coronary Angiography; Coronary Restenosis | 2009 |
Cilostazol-based triple antiplatelet therapy compared to dual antiplatelet therapy in patients with coronary stent implantation: a meta-analysis of 5,821 patients.
Topics: Acute Coronary Syndrome; Aspirin; Blood Vessel Prosthesis; Blood Vessel Prosthesis Implantation; Cil | 2012 |
Cilostazol: potential mechanism of action for antithrombotic effects accompanied by a low rate of bleeding.
Topics: Bleeding Time; Cilostazol; Dose-Response Relationship, Drug; Hemorrhage; Humans; Platelet Aggregatio | 2005 |
Secondary prevention of stroke and transient ischemic attack: is more platelet inhibition the answer?
Topics: Aspirin; Atherosclerosis; Cilostazol; Clinical Trials as Topic; Clopidogrel; Coronary Disease; Dipyr | 2007 |
[Basic principal of the dual antithrombotic therapy achieved by cilostazol].
Topics: Cilostazol; Hemorrhage; Humans; Phosphodiesterase Inhibitors; Tetrazoles; Thrombosis; Vasodilator Ag | 2006 |
11 trials available for cilostazol and Hemorrhage
| Article | Year |
|---|---|
Dual antiplatelet therapy with cilostazol in stroke patients with extracranial arterial stenosis or without arterial stenosis: A subgroup analysis of the CSPS.com trial.
Topics: Aspirin; Cerebral Infarction; Cilostazol; Clopidogrel; Constriction, Pathologic; Drug Therapy, Combi | 2023 |
Dual Antiplatelet Therapy With Cilostazol for Secondary Prevention in Lacunar Stroke: Subanalysis of the CSPS.com Trial.
Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; | 2023 |
DAPT Plus Cilostazol is Better Than Traditional DAPT or Aspirin Plus Ticagrelor as Elective PCI for Intermediate-to-Highly Complex Cases: Prospective, Randomized, PRU-Based Study in Taiwan.
Topics: Aged; Aspirin; Blood Platelets; Cilostazol; Clopidogrel; Diamines; Female; Hemorrhage; Humans; Male; | 2019 |
Adjunctive cilostazol versus double-dose clopidogrel after drug-eluting stent implantation: the HOST-ASSURE randomized trial (Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis-Safety & Effectiveness of Drug-Eluting Stents & Anti-plate
Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug Therapy, | 2013 |
Randomized Angiographic and Intravascular Ultrasound Comparison of Dual-Antiplatelet Therapy vs Triple-Antiplatelet Therapy to Reduce Neointimal Tissue Proliferation in Diabetic Patients.
Topics: Aspirin; Cilostazol; Clopidogrel; Comorbidity; Coronary Angiography; Coronary Artery Disease; Corona | 2017 |
Efficacy of cilostazol-based dual antiplatelet treatment in patients undergoing carotid artery stenting.
Topics: Aged; Aged, 80 and over; Aspirin; Carotid Stenosis; Cilostazol; Clopidogrel; Drug Therapy, Combinati | 2017 |
Efficacy of cilostazol in reducing restenosis in patients undergoing contemporary stent based PCI: a meta-analysis of randomised controlled trials.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Coronary Angiography; Coronary Restenosis | 2009 |
Enhanced platelet inhibition by adjunctive cilostazol to dual antiplatelet therapy after drug-eluting stent implantation for complex lesions.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Clopidogrel; Drug Therapy, Combination; F | 2010 |
Cilostazol reduces the progression of carotid intima-media thickness without increasing the risk of bleeding in patients with acute coronary syndrome during a 2-year follow-up.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Analysis of Variance; Angioplasty, Balloon, Corona | 2011 |
Cilostazol in Acute Ischemic Stroke Treatment (CAIST Trial): a randomized double-blind non-inferiority trial.
Topics: Aged; Aspirin; Cilostazol; Dose-Response Relationship, Drug; Double-Blind Method; Female; Hemorrhage | 2011 |
Long-term safety of cilostazol in patients with peripheral artery disease: the CASTLE study (Cilostazol: A Study in Long-term Effects).
Topics: Aged; Cardiovascular Diseases; Cilostazol; Double-Blind Method; Female; Hemorrhage; Humans; Intermit | 2008 |
21 other studies available for cilostazol and Hemorrhage
| Article | Year |
|---|---|
Comparison of Cilostazol versus Clopidogrel in Addition to Aspirin in Patients with Ischemic Stroke who Underwent Intracranial or Extracranial Artery Stent Implantation.
Topics: Arteries; Aspirin; Cilostazol; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Ischemic | 2023 |
Structural characterization of the optical isomers esomeprazole and omeprazole using the JADER and FAERS databases.
Topics: Adverse Drug Reaction Reporting Systems; Cilostazol; Clopidogrel; Databases, Factual; Drug-Related S | 2023 |
Cilostazol-based triple versus potent P2Y12 inhibitor-based dual antiplatelet therapy in patients with acute myocardial infarction undergoing percutaneous coronary intervention.
Topics: Aged; Asian People; Aspirin; Cilostazol; Clopidogrel; Databases, Factual; Dual Anti-Platelet Therapy | 2020 |
Cilostazol for Chinese Patients with Aspirin Intolerance after Coronary Drug-Eluting Stent Implantation.
Topics: Aspirin; China; Cilostazol; Coronary Artery Disease; Drug-Eluting Stents; Dual Anti-Platelet Therapy | 2020 |
Outcome of Triple Antiplatelet Therapy Including Cilostazol in Elderly Patients with ST-Elevation Myocardial Infarction who Underwent Primary Percutaneous Coronary Intervention: Results from the INTERSTELLAR Registry.
Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; | 2017 |
Safety of cilostazol in peripheral artery disease: a cohort from a primary healthcare electronic database.
Topics: Age Factors; Aged; Aged, 80 and over; Cardiovascular Agents; Cerebrovascular Disorders; Cilostazol; | 2018 |
Adverse Effect of Antithrombotic Medications on Bleeding Events and Comparison of Antithrombotic Agents in Hemodialysis Patients.
Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Diabetic Nephropathies; Drug Monitoring; Female; Fibrinolyti | 2019 |
The safety of triple antiplatelet therapy under thromboelastography guidance in patients undergoing stenting for ischemic cerebrovascular disease.
Topics: Aged; Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhag | 2019 |
Long-term effectiveness and safety of triple versus dual antiplatelet therapy after percutaneous coronary intervention for unprotected left main coronary artery disease.
Topics: Aged; Cerebrovascular Disorders; Cilostazol; Coronary Restenosis; Coronary Stenosis; Coronary Thromb | 2013 |
Platelet inhibition by adjunctive cilostazol suppresses the frequency of cerebral ischemic lesions after carotid artery stenting in patients with carotid artery stenosis.
Topics: Aged; Angioplasty; Aspirin; Brain Ischemia; Carotid Stenosis; Cilostazol; Clopidogrel; Diffusion Mag | 2014 |
Enteric-coated aspirin versus other antiplatelet drugs in acute non-cardioembolic ischemic stroke: post-marketing study in Japan.
Topics: Aged; Aged, 80 and over; Aspirin; Cerebral Hemorrhage; Cerebral Infarction; Cilostazol; Dipyridamole | 2014 |
Cilostazol and outcome in outpatients with peripheral artery disease.
Topics: Aged; Cilostazol; Female; Fibrinolytic Agents; Hemorrhage; Humans; Intermittent Claudication; Male; | 2014 |
Comparative effects of the anti-platelet drugs, clopidogrel, ticlopidine, and cilostazol on aspirin-induced gastric bleeding and damage in rats.
Topics: Animals; Aspirin; Cilostazol; Clopidogrel; Hemoglobins; Hemorrhage; Male; Peroxidase; Platelet Aggre | 2014 |
Cilostazol research in Asia: can it be applied to European and American patients?
Topics: Asia; Cilostazol; Europe; Hemorrhage; Humans; Intracranial Arteriosclerosis; Phosphoric Diester Hydr | 2015 |
Antiplatelet Therapy of Cilostazol or Sarpogrelate with Aspirin and Clopidogrel after Percutaneous Coronary Intervention: A Retrospective Cohort Study Using the Korean National Health Insurance Claim Database.
Topics: Aspirin; Cilostazol; Clopidogrel; Drug-Related Side Effects and Adverse Reactions; Hemorrhage; Human | 2016 |
Clinical Features and Outcomes of Diffuse Alveolar Hemorrhage During Antithrombotic Therapy: A Retrospective Cohort Study.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cilostazol; Clopidogrel; Connective Tissue Diseases; Female | 2016 |
Phosphodiesterase-III inhibitor prevents hemorrhagic transformation induced by focal cerebral ischemia in mice treated with tPA.
Topics: Animals; Astrocytes; Blood-Brain Barrier; Brain Ischemia; Cilostazol; Cyclic Nucleotide Phosphodiest | 2010 |
Post percutaneous coronary intervention antiplatelet therapy: current perceptions, prospects and perplexity.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Clopidogrel; Coronary Restenosis; Drug Resistan | 2011 |
Cilostazol, a phosphodiesterase inhibitor, prevents no-reflow and hemorrhage in mice with focal cerebral ischemia.
Topics: Administration, Oral; Animals; Antigens, CD; Brain; Brain Edema; Brain Ischemia; Calcium-Binding Pro | 2012 |
New modalities and aspects of antiplatelet therapy for stroke prevention.
Topics: Aspirin; Blood Platelets; Cilostazol; Clopidogrel; Drug Design; Drug Resistance; Drug Therapy, Combi | 2006 |
Efficacy and safety of abciximab in combination with cilostazol in patients undergoing stenting.
Topics: Abciximab; Aged; Angina, Unstable; Antibodies, Monoclonal; Cilostazol; Coronary Angiography; Coronar | 2007 |